Medtronic triggers Wyeth, J&J suit
This article was originally published in Clinica
Executive Summary
Wyeth and Johnson & Johnson have reacted to the FDA approval of Medtronic's Endeavor drug-eluting stent (DES) by filing suit against the product. The companies allege that the Endeavor DES, which was approved in February (see Clinica No 1293, p 1), infringes on three patents owned by Wyeth and licensed to J&J. Wyeth's patents - numbers '781, '146 and '728 - relate to the use of rapamycin or sirolimus in stents for patients undergoing angioplasty and vascular disease procedures. Medtronic's DES uses zotarolimus, an analogue of rapamycin and sirolimus. The lawsuit has asked the District Court of New Jersey to block Medtronic from selling the Endeavor DES in the US.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.